Global Cystic Fibrosis Therapeutics Market Forecast 2020-2028

Global Cystic Fibrosis Therapeutics Market Forecast 2020-2028

The global cystic fibrosis therapeutics market is anticipated to grow at a rate of 10.04% during the estimated period of 2020-2028. A rise in incidences of cystic fibrosis across the globe, an increase in medications against cystic fibrosis, and a hike in R&D investments towards the development of drugs to treat cystic fibrosis are boosting the market.

Cystic fibrosis is a disease that is inherited and mainly affects the lungs and other body parts like the kidney, pancreas, and liver. In cystic fibrosis, thick and sticky mucus is produced by the body that may block the lungs and obstruct the pancreas. There is no cure for the fatal disease, but taking proper medication and nutrition to reduce excess mucus produced in the lungs and kidney can help in increasing the patient’s lifespan. The disease is most prevalent in newborns, and has led the researchers towards the development of advanced therapeutics, which may increase the life span of the patients. However, the high costs involved in cystic fibrosis treatment and the introduction of generic drugs impede the market growth. At the same time, the growth of the healthcare industry in developing economies is expected to create profitable opportunities in the future.

The global cystic fibrosis therapeutics market is geographically analyzed based on markets situated in North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of Europe holds the largest market share in terms of revenue, and continues the trend by the end of the forecast period. This is attributed to the presence of key players investing largely in the development of new technologies. The market region of Europe is predicted to be the fastest-growing market in terms of revenue. The major factor driving the growth is the surge in incidences of cystic fibrosis in the region.

Abbott Laboratories, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Pharmaxis Ltd, Novartis International AG, etc. are some of the leading companies registering their presence in the global market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Advancements In The Cystic Fibrosis Therapeutics Treatment
3.2.2. Increasing Incidence Of Cystic Fibrosis (Cf)
3.2.3. Rise In The R&D Of Novel Cystic Fibrosis Therapeutics
3.3. Key Restraints
3.3.1. Stringent Regulation
3.3.2. Low Awareness Among Developing Economies
4. Key Analytics
4.1. Porter’s Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’s Power
4.1.4. Supplier’s Power
4.1.5. Competitive Rivalry
4.2. Pestel Analysis
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insights
5. Market By Route Of Administration
5.1. Inhale
5.2. Oral
6. Market By Drug Class
6.1. Cftr Modulators
6.2. Bronchodilators
6.3. Mucolytic
6.4. Pancreatic Enzyme Supplements
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. The United Kingdom
7.2.2. France
7.2.3. Germany
7.2.4. Italy
7.2.5. Russia
7.2.6. Belgium
7.2.7. Poland
7.2.8. Rest Of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Australia & New Zealand
7.3.5. South Korea
7.3.6. Thailand
7.3.7. Indonesia
7.3.8. Vietnam
7.3.9. Rest Of Asia Pacific
7.4. Rest Of World
7.4.1. Latin America
7.4.2. Middle East & Africa
8. Company Profiles
8.1. Abbott Laboratories
8.2. Abbvie Inc
8.3. Agilent Technologies Inc
8.4. Allergan Plc
8.5. F. Hoffmann-la Roche
8.6. Gilead Sciences Inc
8.7. Glaxosmithkline Plc
8.8. Johnson & Johnson
8.9. Mylan N.V
8.10. Novartis Ag
8.11. Perkinelmer
8.12. Pfizer Inc
8.13. Pharmaxis Ltd
8.14. Teva Pharmaceutical Industries Ltd
8.15. Vertex Pharmaceuticals Incorporated

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook